Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.68 |
| ▸ | MPO | P05164 | 10/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | XDH | P47989 | 7/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10288923 | 0.96 | ALDH1A1 (0.79) | ALDH1A1HSD17B10MPOMAPK1XDH | |
| Hydrochloric Acid SCHEMBL2732441 | 0.95 | ALDH1A1 (0.77) | ALDH1A1HSD17B10MPOMAPK1XDH | |
| SCHEMBL2730558 | 0.85 | ALDH1A1 (0.73) | ALDH1A1HSD17B10MPOMAPK1XDH | |
| SCHEMBL2731426 | 0.84 | ALDH1A1 (0.74) | ALDH1A1HSD17B10MPOMAPK1XDH | |
| SCHEMBL18708215 | 0.82 | ALDH1A1 (1.00) | ALDH1A1HSD17B10MPOMAPK1XDH | |
| SCHEMBL2730707 | 0.79 | MPO (1.00) | ALDH1A1MPOXDHL3MBTL1HTT | |
| SCHEMBL2723795 | 0.78 | MPO (0.92) | ALDH1A1MPOXDH | |
| SCHEMBL2730381 | 0.77 | MPO (0.90) | ALDH1A1MPOXDH | |
| SCHEMBL85957 | 0.77 | IMPDH2 (0.74) | ALDH1A1HSD17B10MAPK1L3MBTL1HTT | |
| SCHEMBL2731128 | 0.75 | MPO (0.67) | ALDH1A1HSD17B10MPOMAPK1XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150110723-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2015-04-23 | — | — | US | claimed |
| WO-2013181135-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2013-12-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150110723-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | NOX3, NOX1, NOX5 | ALDH1A1 659/4885HSD17B10 3059/4885MPO 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.